Lisinopril
Ace Inhibitors, Plain
Sold as ZESTRIL · ZESTORETIC · ZESTORETIC 10
- Drug class
- Ace Inhibitors, Plain
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 150
- FDA reports (12 mo)
- 10,948
Overview
Plain-language summary, compiled from the cited regulatory records
Lisinopril is a medication classified as an ACE inhibitor [1]. It is approved for the treatment of hypertension, also known as high blood pressure [1]. By lowering blood pressure, lisinopril helps to reduce the risk of serious cardiovascular events, such as strokes and heart attacks [1]. These benefits have been demonstrated in clinical trials involving various types of blood pressure medications [1].
Lisinopril is available under different brand names, including Zestoretic [1]. In the past 12 months, there have been 10,948 adverse event reports associated with this active ingredient [2]. The most frequently reported adverse events include fatigue, off-label use, diarrhea, nausea, and headache [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 92 | May 22, 2026 |
| CA Canada | Health Canada | 33 | January 6, 2026 |
| US United States | FDA | 25 | May 22, 2026 |
GBUnited Kingdom· MHRA
92 products
Uses
Hypertension:
Treatment of hypertension.
Heart failure:
Treatment of symptomatic heart failure.
Acute myocardial infarction:
Short-term (6 weeks) treatment of haemodynamically stable patients within 24 hours of an acute myocardial infarction. 1).
How to take
CACanada· Health Canada
33 products
Uses
LISINOPRIL TABLETS (lisinopril) is indicated in adults for: • Hypertension: in the treatment of essential hypertension and in renovascular hypertension, alone or in combination with thiazide diuretics. A great majority of patients (>80%) with severe hypertension required combination therapy.
• Heart Failure: in the management of symptomatic congestive heart failure as adjunctive treatment with diuretics, and where appropriate, digitalis. Treatment with LISINOPRIL TABLETS should be initiated under close medical supervision, usually in a hospital.
High doses of LISINOPRIL TABLETS reduce the risk of the combined outcomes of mortality and hospitalization (see 4 DOSAGE AND ADMINISTRATION and 10 CLINICAL PHARMACOLOGY). • Acute Myocardial Infarction: in the treatment of hemodynamically stable patients as early as within 24 hours following acute myocardial infarction, to improve survival.
Patients should receive, as appropriate, the standard recommended treatments such as thrombolytics, ASA and beta blocker(s). Therapy with LISINOPRIL TABLETS should be reassessed after 6 weeks. If there is no evidence of symptomatic or asymptomatic left ventricular dysfunction, treatment with LISINOPRIL TABLETS can be stopped.
USUnited States· FDA
25 products
Uses
1 Hypertension Lisinopril tablets, USP, are indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions.
These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake.
Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).
Drug interactions
Known interactions involving Lisinopril. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 600. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL367220201 · revised May 22, 2026
- [2]Health Canada (DPD) · 02554488 · revised January 6, 2026
- [3]FDA DailyMed · 02c23f9c-f3cf-43… · revised May 22, 2026 [PDF]
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.